Pharma Pulse 3/3/25: How Tariffs Will Drive Up Pharmaceutical Costs, Medicaid Cuts Could Shift Up to $1.1 Trillion in Costs to States & more

How Tariffs Will Drive Up Pharmaceutical Costs & Which Drug Categories Will Be Most Affected

In this Pharmaceutical Executive video interview, Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, highlighting that tariffs will initially affect pharmaceutical companies, particularly those dealing with branded medications and generics. He notes that tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts. Digital health platforms like UpScriptHealth aim to reduce friction and costs in healthcare, potentially offsetting tariff impacts. Ax emphasizes the importance of telehealth in ensuring medication availability and the strategic partnerships between digital health platforms and pharma companies to improve patient care and access. He also praises Pfizer's approach to delivering comprehensive care rather than just selling medications.

Medicaid Cuts Could Shift Up to $1.1 Trillion in Costs to States

If federal Medicaid spending per enrollee is capped, states will have to make up for an estimated $700 billion to $1.1 trillion in funding reductions from the federal government over the next ten years, according to a new analysis by the Urban Institute, supported by the Robert Wood Johnson Foundation.

What’s Ahead for AI

This special report explores the newest developments in artificial intelligence, from powering the brains of humanoid robots to a far-reaching strategy at America’s biggest bank, JPMorgan.

Predictmedix AI Launches Advanced AI Health Stations to Target the US Market

Predictmedix AI Inc. announced that it is launching its enhanced Smart Health AI Stations across the United States, positioning itself to capitalize on the rapidly expanding population health management market.

Archbow Consulting on LinkedIn

Archbow Consulting's Rob Besse, Senior Vice President, Principal, and Subject Matter Expert in Distribution, teamed up with Pharmaceutical Commerce Magazine to detail several key questions pharma should consider in determining their Current Market Leverage (CML) before wholesaler negotiations. Click the link to read the article.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs